No connection

Search Results

MDWD vs MGNX

MDWD
MediWound Ltd.
BEARISH
Price
$17.65
Market Cap
$226.8M
Sector
Healthcare
AI Confidence
95%
MGNX
MacroGenics, Inc.
BEARISH
Price
$3.47
Market Cap
$220.6M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
MDWD
--
MGNX
--
Forward P/E
MDWD
-8.13
MGNX
-3.58
P/B Ratio
MDWD
5.19
MGNX
3.95
P/S Ratio
MDWD
13.38
MGNX
1.48
EV/EBITDA
MDWD
-7.51
MGNX
-1.03

Profitability

Gross Margin
MDWD
19.19%
MGNX
-22.53%
Operating Margin
MDWD
-417.78%
MGNX
-29.34%
Profit Margin
MDWD
-140.8%
MGNX
-49.91%
ROE
MDWD
-63.86%
MGNX
-86.94%
ROA
MDWD
-19.77%
MGNX
-17.56%

Growth

Revenue Growth
MDWD
-68.0%
MGNX
113.0%
Earnings Growth
MDWD
--
MGNX
--

Financial Health

Debt/Equity
MDWD
0.2
MGNX
0.66
Current Ratio
MDWD
2.33
MGNX
5.1
Quick Ratio
MDWD
2.16
MGNX
4.71

Dividends

Dividend Yield
MDWD
--
MGNX
--
Payout Ratio
MDWD
0.0%
MGNX
0.0%

AI Verdict

MDWD BEARISH

MDWD exhibits severe financial distress as evidenced by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. The company is experiencing a catastrophic operational collapse with revenue plummeting by 68% YoY and operating margins sitting at -417.78%. While the balance sheet remains liquid with a Current Ratio of 2.33 and low debt, these are lagging indicators that cannot offset the rapid erosion of the top and bottom lines. There is a dangerous divergence between the fundamental decay and the 'Strong Buy' analyst consensus, suggesting the stock is priced on speculative hopes rather than data-driven value.

Strengths
Low Debt/Equity ratio of 0.20
Strong liquidity with a Current Ratio of 2.33
Healthy Quick Ratio of 2.16
Risks
Severe revenue contraction (-68% YoY and Q/Q)
Extreme operational inefficiency (Operating Margin -417.78%)
Critical Piotroski F-Score (1/9) signaling fundamental weakness
MGNX BEARISH

MGNX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the company shows explosive revenue growth (113% YoY) and maintains a strong liquidity position (Current Ratio 5.10), it suffers from negative gross margins and a consistent track record of missing earnings estimates. The recent 1-year price surge appears decoupled from fundamental value, as the company remains deeply unprofitable with a catastrophic ROE of -86.94%.

Strengths
Exceptional YoY revenue growth of 113%
Strong short-term liquidity with a Current Ratio of 5.10
Manageable Debt/Equity ratio of 0.66
Risks
Critical fundamental health (Piotroski F-Score 0/9)
Negative gross margins (-22.53%) indicating an unsustainable cost structure
Severe earnings volatility and frequent misses (Average surprise -286.67%)

Compare Another Pair

MDWD vs MGNX: Head-to-Head Comparison

This page compares MediWound Ltd. (MDWD) and MacroGenics, Inc. (MGNX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile